The relationship between the number of available therapeutic options and government payer (medicare part D) spending on topical drug products

Author:

Kwa Michael C.ORCID,Tegtmeyer KyleORCID,Welty Leah J.,Raney Sam G.,Luke Markham C.,Xu Shuai,Kong BettyORCID

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Reference16 articles.

1. National Health Expenditure Data Historical (2018) Centers for Medicare & Medicaid Services. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsHistorical.html. Accessed 3 Mar 2019

2. Generic Drugs Under Medicare: Part D Generic Drug Prices Declined Overall, but Some Had Extraordinary Price Increases (2016) U.S. Government Accountability Office. https://www.gao.gov/products/GAO-16-706. Accessed 3 Mar 2019

3. Walter JR, Xu S (2015) Topical drug innovation from 2000 through 2014. JAMA Dermatol 151:792–794

4. Kinch MS, Haynesworth A, Kinch SL, Hoyer D (2014) An overview of FDA-approved new molecular entities: 1827–2013. Drug Discovery Today 19:1033–1039

5. Welty LJ, Rasmussen LV, Baldridge AS, Whitley E (2016) StatTag. Galter Health Sciences Library, Chicago. doi: https://doi.org/10.18131/G3K76

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3